Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 11;10(6):e70302.
doi: 10.1002/lio2.70302. eCollection 2025 Dec.

Succinate Dehydrogenase Pathogenic Variants Among Older Adults With Head and Neck Paragangliomas

Nikhil Bellamkonda  1 , Anne Naumer  2 , Luke O Buchmann  1 , Hilary C McCrary  1 , Mana Espahbodi  1 , Neil S Patel  1
Affiliations

Succinate Dehydrogenase Pathogenic Variants Among Older Adults With Head and Neck Paragangliomas

Nikhil Bellamkonda et al. Laryngoscope Investig Otolaryngol. .

Erratum in

Abstract

Introduction: The objective of this study was to determine the proportion of patients over the age of 50 who have HNPGL related to an SDH PV.

Methods: Patients seen at a single, tertiary-care academic medical center diagnosed with a new HNPGL over the age of 50 were included and analyzed.

Results: One hundred and eleven individuals (155 tumors) were included. Eighty (72%) patients underwent genetic testing. Twenty-one PVs of known significance were identified (SDHA in 1, SDHB in 11, SDHC in 5, SDHD in 3, and FH in 1). The rate of SDH PVs in the tested group was 25%. The median age in patients with a PV was 60 years (IQR: 54-67) years, compared to 67 years (IQR: 59-71) in those without.

Conclusions: Patients diagnosed with a HNPGL over the age of 50 are still at risk for having an SDH PV. Older patients with HNPGL and their families should still be referred for genetic testing.

Level of evidence: IV.

Keywords: SDH; carotid body tumors; glomus tympanicum (middle ear paraganglioma); jugular paragangliomas; paraganglioma.

PubMed Disclaimer

Conflict of interest statement

Neil S. Patel, MD, serves as a consultant for Viridian Therapeutics, has received research support from Cochlear Corp., and has functioned as a speaker on behalf of IotaMotion and Zeiss.The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Incidence of HNPGL associated PV per decade. *N = 21.
FIGURE 2
FIGURE 2
Distribution of tumor location.
See this image and copyright information in PMC

References

    1. Sandow L., Thawani R., Kim M. S., and Heinrich M. C., “Paraganglioma of the Head and Neck: A Review,” Endocrine Practice 29, no. 2 (2023): 141–147, 10.1016/j.eprac.2022.10.002. - DOI - PMC - PubMed
    1. Woolen S. and Gemmete J. J., “Paragangliomas of the Head and Neck,” Neuroimaging Clinics of North America 26, no. 2 (2016): 259–278, 10.1016/j.nic.2015.12.005. - DOI - PubMed
    1. Majewska A., Budny B., Ziemnicka K., Ruchała M., and Wierzbicka M., “Head and Neck Paragangliomas—A Genetic Overview,” International Journal of Molecular Sciences 21, no. 20 (2020): 7669, 10.3390/ijms21207669. - DOI - PMC - PubMed
    1. Baysal B. E., Ferrell R. E., Willett‐Brozick J. E., et al., “Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma,” Science (80‐) 287, no. 5454 (2000): 848–851, 10.1126/science.287.5454.848. - DOI - PubMed
    1. Bausch B., Schiavi F., Ni Y., et al., “Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene‐Informed Prevention,” JAMA Oncology 3, no. 9 (2017): 1204–1212, 10.1001/jamaoncol.2017.0223. - DOI - PMC - PubMed

LinkOut - more resources